Prominent Chemopreventive and Chemoenhancing Effects for Resveratrol: Unraveling Molecular Targets and the Role of C-Reactive Protein
Abstract
Background: Resveratrol (RSVL) claims health benefits that pertain to the consumption of red wine/grapes. We currently evaluated the chemopreventive effects of RSVL, as well as its possible chemoenhancing effects when given with cisplatin (CP), in the Ehrlich ascites carcinoma (EAC) solid tumor model. Further, we monitored concomitant changes in serum levels of C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), leukocytic count (LC) and lipid peroxidation (measured as malondialdehyde, MDA). Results: EAC-bearing mice exhibited a markedly elevated LC (2 fold), CRP (11 fold) and MDA levels (2.7 fold). RSVL (20 or 40 mg/kg) elicited significant, dose-dependent reductions in tumor size (58 and 78%, respectively), as well as in LC (normalized), CRP (down to 2 fold), TNF-α (down to near control levels) and MDA levels (normalized). The chemopreventive effects for CP (55% reduction in cell growth) was significantly lower than that of RSVL (40 mg/kg, 79% inhibition). Interestingly, coadministration of RSVL (20 mg/kg) markedly enhanced the chemoprevention of CP. Correlation studies revealed a high degree of positive association between tumor growth and CRP (r = 0.89) and leukocytosis (r = 0.86), thus attesting to a diagnostic/prognostic role for CRP in this solid tumor. Conclusion: RSVL elicited remarkable cytotoxicity on its own and appreciably augmented those of CP as well. The extent of tumor progression in various mouse groups was highly reflected by CRP levels. RSVL acts prominently by reducing inflammatory cytokines, leukocytosis and oxidative stress.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
RSV is a well-known activator of SIRT1.
“Moreover, RSV is a well-known activator of SIRT1 and our previous study also found that RSV improved hepatic steatosis partially by inducing autophagy via the SIRT1 signaling pathway in vitro and in vivo (36–38).”
RSV improved hepatic steatosis partially by inducing autophagy via the SIRT1 signaling pathway in vitro and in vivo.
“Moreover, RSV is a well-known activator of SIRT1 and our previous study also found that RSV improved hepatic steatosis partially by inducing autophagy via the SIRT1 signaling pathway in vitro and in vivo (36–38).”
Cites
Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction
Ohkawa, H., Ohishi, N., & Yagi, K. (1979) · Analytical Biochemistry · doi:10.1016/0003-2697(79)90738-3 · Cited by 29,460 · see citing works
Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies.
Aggarwal, B. B., Bhardwaj, A., Aggarwal, R. S., Seeram, N. P., Shishodia, S., & Takada, Y. (2004) · PubMed · Cited by 1,383 · see citing works
Geran, R. I., Greenberg, N. H., MacDonald, M., Schumacher, A., & Abbott, B. J. (1972) · Cancer chemotherapy reports. Part 1 · Cited by 1,128 · see citing works
Subbaramaiah, K., Chung, W. J., Michaluart, P., TELANG, N. T., Tanabe, T., Inoue, H., Jang, M., Pezzuto, J. M., & Dannenberg, A. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.34.21875 · Cited by 786 · see citing works
Resveratrol: A multitargeted agent for age-associated chronic diseases
Harikumar, K. B., & Aggarwal, B. B. (2008) · Cell Cycle · doi:10.4161/cc.7.8.5740 · Cited by 552 · see citing works
Galati, G. (2002) · Toxicology · doi:10.1016/s0300-483x(02)00198-1 · Cited by 530 · see citing works
Heikkilä, K., Ebrahim, S. B. J., & Lawlor, D. A. (2007) · Journal of Epidemiology & Community Health · doi:10.1136/jech.2006.051292 · Cited by 429 · see citing works
Banerjee, S., Bueso-Ramos, C., & Aggarwal, B. B. (2002) · PubMed · Cited by 423 · see citing works
A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol
Gusman, J. (2001) · Carcinogenesis · doi:10.1093/carcin/22.8.1111 · Cited by 387 · see citing works
Resveratrol, a remarkable inhibitor of ribonucleotide reductase
Fontecave, M., Lepoivre, M., Elleingand, E. F., Gerez, C., & Guittet, O. (1998) · FEBS Letters · doi:10.1016/s0014-5793(97)01572-x · Cited by 383 · see citing works
The role of C-reactive protein as a prognostic indicator in advanced cancer
Mahmoud, F. A., & Rivera, N. I. (2002) · Current Oncology Reports · doi:10.1007/s11912-002-0023-1 · Cited by 325 · see citing works
Afaq, F., Adhami, V. M., & Ahmad, N. (2003) · Toxicology and Applied Pharmacology · doi:10.1016/s0041-008x(02)00014-5 · Cited by 262 · see citing works
Hong, J., Smith, T. J., Ho, C., August, D. A., & Yang, C. S. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00767-5 · Cited by 262 · see citing works
Lin, M., Yen, M., Lin, C., & Kuo, M. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.5.1029 · Cited by 208 · see citing works
Li, Z. (2002) · Carcinogenesis · doi:10.1093/carcin/23.9.1531 · Cited by 169 · see citing works
Mahyar-Roemer, M., Katsen, A. D., Mestres, P., & Roemer, K. (2001) · International Journal of Cancer · doi:10.1002/ijc.1516 · Cited by 162 · see citing works
Chirino, Y. I., Hernández‐Pando, R., & Pedraza‐Chaverrí, J. (2004) · BMC Pharmacology · doi:10.1186/1471-2210-4-20 · Cited by 149 · see citing works
Du, B., Jiang, L., Xia, Q., & Zhong, L. (2005) · Chemotherapy · doi:10.1159/000090238 · Cited by 144 · see citing works
Cadenas, S., & Barja, G. (1999) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(99)00019-2 · Cited by 138 · see citing works
Molecular mechanisms of the chemopreventive effects of resveratrol and its analogs in carcinogenesis
Ulrich, S., Wolter, F., & Stein, J. M. (2005) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200400081 · Cited by 138 · see citing works
Chen, Y., Tseng, S., Lai, H., & Chen, W. (2004) · Surgery · doi:10.1016/j.surg.2004.01.017 · Cited by 127 · see citing works
El‐Mowafy, A. M. (2003) · Carcinogenesis · doi:10.1093/carcin/bgg015 · Cited by 117 · see citing works
Self-citationQuantitative evaluation of anticancer agent activity in experimental animals
Schabel, F. M., Griswold, D. P., Laster, W. R., Corbett, T. H., & Lloyd, H. H. (1977) · Pharmacology & Therapeutics Part A Chemotherapy Toxicology and Metabolic Inhibitors · doi:10.1016/0362-5478(77)90004-3 · Cited by 113 · see citing works
C‐reactive protein as a prognostic marker for men with androgen‐independent prostate cancer
Beer, T. M., Lalani, A. S., Lee, S. J., Mori, M., Eilers, K. M., Curd, J. G., Henner, W. D., Ryan, C. W., Venner, P. M., Ruether, J. D., et al. (2008) · Cancer · doi:10.1002/cncr.23461 · Cited by 106 · see citing works
Rezk, Y. A., Balulad, S. S., Keller, R. S., & Bennett, J. A. (2006) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.11.030 · Cited by 105 · see citing works
Quercetin Is Able to Demethylate the p16INK4a Gene Promoter
Tan, S., Wang, C., Lu, C., Zhao, B., Cui, Y., Shi, X., & Ma, X. (2008) · Chemotherapy · doi:10.1159/000166383 · Cited by 104 · see citing works
Sengottuvelan, M., Senthilkumar, R., & Nalini, N. (2006) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2006.03.008 · Cited by 100 · see citing works
Schirner, M., Hoffmann, J., Menrad, A., & Schneider, M. R. (1998) · PubMed · Cited by 95 · see citing works
Chemotherapeutic potential of the chemopreventive phytoalexin resveratrol
Pervaiz, S. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2004.11.001 · Cited by 88 · see citing works
Resveratrol Inhibits Cyclooxygenase‐2 Transcription in Human Mammary Epithelial Cells
Subbaramaiah, K., Michaluart, P., Chung, W. J., Tanabe, T., TELANG, N. T., & Dannenberg, A. J. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb08737.x · Cited by 88 · see citing works
Isolation of C-reactive protein by affinity chromatography.
Pepys, M. B., Dash, A. C., & Ashley, M. J. (1977) · PubMed · Cited by 78 · see citing works
Lippincott's Illustrated Reviews: Pharmacology, 4th Edition
Pazdernik, T. L. (2009) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e3181a21294 · Cited by 59 · see citing works
Lamb, G. W. A., McArdle, P., Ramsey, S., McNichol, A., Edwards, J., Aitchison, M., & McMillan, D. C. (2008) · British Journal of Urology · doi:10.1111/j.1464-410x.2008.07666.x · Cited by 52 · see citing works
Comparison of the growth of the Ehrlich ascites tumor in male and female mice.
Vincent, P., & Nicholls, A. (1967) · PubMed · Cited by 36 · see citing works
El‐Mowafy, A. M., Alkhalaf, M., & El‐Kashef, H. A. (2007) · Archives of Medical Research · doi:10.1016/j.arcmed.2007.09.010 · Cited by 25 · see citing works
Self-citationIn vivo inhibition of TNFα-induced vascular permeability by resveratrol
Fulgenzi, A., Bertelli, A. A. E., Magni, E., Ferrero, E., & Ferrero, M. E. (2001) · Transplantation Proceedings · doi:10.1016/s0041-1345(01)02015-2 · Cited by 25 · see citing works
Thongphasuk, P., Stremmel, W., & Chamulitrat, W. (2007) · Chemotherapy · doi:10.1159/000112314 · Cited by 20 · see citing works
Comparative nephrotoxicity of cisplatin and new octahedral Pt(IV) complexes
Kim, W.-K., & Kwon, Y.-E. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0366-7 · Cited by 11 · see citing works
Langdon, S. P., Ritchie, A., Muir, M., Dodds, M., Howie, A. F., Leonard, R. C., Stockman, P. K., & Miller, W. R. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00372-9 · Cited by 10 · see citing works
Flagged first, then by citations
1 of the 40 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Chen, M.-L., Yi, L., Zhang, Y., Zhou, X., Ran, L., Yang, J., Zhu, J.-D., Zhang, Q.-Y., & Mi, M.-T. (2016) · mBio · doi:10.1128/mbio.02210-15 · Cited by 754 · see citing works
Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Tomé‐Carneiro, J., Larrosa, M., González‐Sarrías, A., Tomás-Barberán, F. A., García‐Conesa, M., & Espı́n, J. C. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990407 · Cited by 451 · see citing works
What Is New for an Old Molecule? Systematic Review and Recommendations on the Use of Resveratrol
Vang, O., Ahmad, N., Baile, C. A., Baur, J. A., Brown, K., Csiszár, A., Das, D. K., Delmas, D., Gottfried, C., Lin, H., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019881 · Cited by 433 · see citing works
El-Azab, M. F., Attia, F. M., & El‐Mowafy, A. M. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.02.010 · Cited by 102 · see citing works
Self-citationClinical Studies on the Treatment of Cancer Cachexia with Megestrol Acetate plus Thalidomide
Wen, H., Li, X., Cao, Y.-Z., Zhang, C., Yang, F., Shi, Y.-M., & Peng, L. (2012) · Chemotherapy · doi:10.1159/000346446 · Cited by 73 · see citing works
Zhou, R., Yi, L., Ye, X., Zeng, X., Liu, K., Qin, Y., Zhang, Q., & Mi, M. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000495898 · Cited by 67 · see citing works
El‐Mowafy, A. M., Salem, H. A., Al-Gayyar, M. M. H., El‐Mesery, M., & El-Azab, M. F. (2011) · Natural Product Research · doi:10.1080/14786419.2010.533669 · Cited by 53 · see citing works
Self-citationResveratrol represses YKL-40 expression in human glioma U87 cells
Zhang, W., Murao, K., Zhang, X., Matsumoto, K., Diah, S., Okada, M., Miyake, K., Kawai, N., Zhou, F., & Tamiya, T. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-593 · Cited by 40 · see citing works
Yang, M., Chung, S., Floegel, A., Song, W. O., Koo, S. I., & Chun, O. K. (2013) · European Journal of Nutrition · doi:10.1007/s00394-012-0491-5 · Cited by 38 · see citing works
Xiong, W., Yin, A., Mao, X., Zhang, W., Huiyong, H., & Zhang, X. (2015) · Oncology Letters · doi:10.3892/ol.2015.3888 · Cited by 28 · see citing works
Yeap, S. K., Yusof, H. M., Mohamad, N. E., Beh, B. K., Ho, W. Y., Ali, N. M., Alitheen, N. B., Koh, S. P., & Long, K. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/708464 · Cited by 26 · see citing works
Lachenmeier, D. W., Godelmann, R., Witt, B., Riedel, K., & Rehm, J. T. (2013) · International Journal of Cancer · doi:10.1002/ijc.28336 · Cited by 25 · see citing works
Kaminski, B. M., Weigert, A., Scherzberg, M.-C., Ley, S., Gilbert, B., Brecht, K., Brüne, B., Steinhilber, D., Stein, J. M., & Ulrich-Rückert, S. (2014) · APOPTOSIS · doi:10.1007/s10495-014-0988-x · Cited by 25 · see citing works
Focus on the Use of Resveratrol in Bladder Cancer
Zucchi, A., Claps, F., Pastore, A. L., Perotti, A., Biagini, A., Sallicandro, L., Gentile, R., Caglioti, C., Palazzetti, F., & Fioretti, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054562 · Cited by 21 · see citing works
Mazidi, M., Kengne, A. P., Katsiki, N., Mikhailidis, D. P., & Banach, M. (2018) · British Journal Of Nutrition · doi:10.1017/s0007114518002581 · Cited by 21 · see citing works
Wang, D., Duan, L., Tu, Z., Yan, F., Zhang, C., Xu, L. L., Cao, Y., & Wen, H. (2016) · Chemotherapy · doi:10.1159/000443367 · Cited by 18 · see citing works
Zunino, S. J. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1316 · Cited by 17 · see citing works
Elrazik, N. A. A., El‐Mesery, M., El-Karef, A. A., Eissa, L. A., & Gayar, A. M. E. (2019) · Egyptian Journal of Basic and Applied Sciences · doi:10.1080/2314808x.2019.1682331 · Cited by 14 · see citing works
Self-citationElrazik, N. A. A., El‐Mesery, M., El-Karef, A. A., Eissa, L. A., & Gayar, A. M. E. (2021) · Nutrition and Cancer · doi:10.1080/01635581.2020.1871496 · Cited by 14 · see citing works
Self-citationDavid, I. M. B., Fernandes, F. D. S., Ferreira, J. B. D. S. S., Lüdtke, D. D., Martins, D. F., Bobinski, F., da Silva, T. B. G. C., Buffon, L. D., Kopper, M. B. R., da Silva, G. S., et al. (2018) · Nutrition Research · doi:10.1016/j.nutres.2018.11.005 · Cited by 10 · see citing works
Reduction of Hepatotoxicity Induced by Doxorubicin
Bengaied, D., Ribeiro, A. J., Amri, M., Scherman, D., & Arnaud, P. (2017) · Journal of Integrative Oncology · doi:10.4172/2329-6771.1000193 · Cited by 9 · see citing works
Herbal Therapy: Can Omics Technology Create Order from Chaos?
El‐Mowafy, A. M. (2012) · Biochemistry & Analytical Biochemistry · doi:10.4172/2161-1009.1000e130 · Cited by 5 · see citing works
Self-citationBeetch, M., & Stefañska, B. (2019) · Springer eBooks · doi:10.1007/978-3-319-55530-0_104 · Cited by 3 · see citing works
Beetch, M., & Stefañska, B. (2017) · Springer eBooks · doi:10.1007/978-3-319-31143-2_104-1
- Authors
- El-Mowafy, A. M., El-Mesery, M. E., Salem, H. A., Al-Gayyar, M. M., & Darweish, M. M.
- Affiliations
- Mansoura University (EG)
- Venue
- Chemotherapy
- Publisher
- S. Karger AG
- Published
- 2010
- Volume
- 56
- Issue
- 1
- Pages
- 60-65
- ISSN
- 0009-3157 (ISSN-L)
- 1421-9794
- OpenAlex
- W2041490167
- Cited by
- 24
- References
- 40
- Citations by year
- 2023: 1 · 2021: 1 · 2019: 2 · 2018: 3 · 2017: 2 · 2016: 2 · 2015: 1 · 2014: 1 · 2013: 4 · 2012: 2
- FWCI
- 1.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Chemotherapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Health Sciences › Medicine › Biochemistry › Phytochemicals and Antioxidant Activities
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer and biochemical research
- Keywords
- resveratrol, chemoprevention, cisplatin, Ehrlich ascites carcinoma, C-reactive protein, TNF-α, leukocytosis, lipid peroxidation, malondialdehyde, oxidative stress, inflammation, red wine, solid tumors, prognostic factors
- MeSH terms
- Resveratrol, Animals, Antineoplastic Combined Chemotherapy Protocols, C-Reactive Protein, Carcinoma, Ehrlich Tumor, Cisplatin, Female, Leukocyte Count, Malondialdehyde, Stilbenes, Tumor Necrosis Factor-alpha, Anticarcinogenic Agents, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review